August 14, 2014
The Alliance for Safe Biologic Medicines (ASBM), along with dozens of patient organizations, write Commissioner Hamburg to encourage the FDA to adopt a policy of distinguishable nonproprietary names for biosimilars and to issue guidance reflecting distinguishable naming as a priority for the well-being of patients. Read full letter here.
August 7, 2014
ARLINGTON, VA – Michael Reilly, executive director of the Alliance for Safe Biologic Medicines (ASBM) today announced pediatric rheumatologist and current ASBM International Advisory Board (IAB) member, Harry L. Gewanter, MD, FAAP, FACR as ASBM’s incoming chairman. In addition, Philip Schneider, MS, FASHP, Professor and Associate Dean at the University of Arizona, College of Pharmacy […]
August 6, 2014
The Idaho Board of Pharmacy held a hearing on August 5th and 6th regarding proposed regulations for the treatment of biosimilars in their state. View ASBM letter here.
August 6, 2014
The Idaho Board of Pharmacy held a hearing on August 5th and 6th regarding proposed regulations for the treatment of biosimilars in their state. View ASBM letter here.
August 1, 2014
View letter here.
August 1, 2014
View letter here.
July 18, 2014
A new RetireSafe survey, published July 15th, finds seniors largely are unaware of “biosimilar” drugs and overwhelmingly support strong patient safeguards for biosimilar development and FDA approval. In the survey, senior respondents supported robust clinical trials, unique names for biosimilar drugs, as well as physician and patient notification of biosimilar substitution. To view the RetireSafe […]
July 9, 2014
See article here.
